XML 26 R16.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT REPORTING
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
Until the closing of the Merger, which occurred subsequent to September 30, 2025, the Company has been concentrated on developing treatments for cancers caused by dysregulated gene expression. The current pipeline consists of two small molecule drugs: (1) SP-3164, a targeted protein degrader, and (2) seclidemstat (“SP-2577”), a targeted protein inhibitor. The Company does not have any revenue generating products.

For the nine months ended September 30, 2025 and 2024, the Company identified one operating and reportable segment relating to its operations. The Company defines its operating segment based on internally reported financial information that is regularly reviewed by the Chief Operating Decision Maker (the "CODM"), its acting Chief Executive Officer. The CODM reviews the segment’s loss based on net loss reported on the consolidated statement of operations.

The Company’s CODM views specific categories within research and development expenses and general and administrative expenses as significant given the direct correlation between cash burn as a pre-revenue company. The table below is a summary of the segment loss, including significant segment expenses:
Three-Months Ended
September 30
Nine-Months Ended
September 30
2025202420252024
Expenses:
Research and development:
SP-316420,76948,20150,212261,061
SP-257741,05789,033203,529333,622
General and administrative:
Professional services and Consulting368,400418,1272,117,5091,751,024
Personnel cost180,897216,838612,9381,305,818
Facility cost284,007234,272595,202594,078
Loss from operations895,1301,006,4713,579,3904,245,603
Interest income, net21,66334,35038,565133,759
Net loss
$
873,467
$
972,121
$
3,540,825
$
4,111,844